AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition
Potential Combination With Farxiga
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
You may also be interested in...
Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.
Biopharma executives and investors descended on San Francisco again, but the numbers seemed fewer, the weather was volatile and the outlook for the sector remained uncertain.
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.